MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.990
+0.050
+1.01%
Closed 17:38 09/24 EDT
OPEN
4.810
PREV CLOSE
4.940
HIGH
5.11
LOW
4.780
VOLUME
607.14K
TURNOVER
--
52 WEEK HIGH
11.52
52 WEEK LOW
4.480
MARKET CAP
233.13M
P/E (TTM)
-2.1715
1D
5D
1M
3M
1Y
5Y
TENX: Second Quarter Results
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
Benzinga · 1d ago
BRIEF-RedHill Biopharma Settles Movantik Patent Litigation With Aurobindo
reuters.com · 3d ago
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
and , /PRNewswire/ -- (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered ...
PR Newswire - PRF · 3d ago
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
Zacks · 09/15 15:40
HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.
Benzinga · 09/15 10:08
HC Wainwright Trims Redhill Biopharma's Price Target to $21 From $23, Keeps Buy Rating
MT Newswires · 09/15 07:42
Hot Stocks: Macau gambling woes; FCEL earnings; CROX hits high; WEBR sets low; RDHL drops on clinical data
While state governments in the U.S. have largely loosened restrictions on gambling in recent years, there are reports that Macau might be taking the opposite approach. Speculation of stepped-up oversight
Seekingalpha · 09/14 21:56
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb
Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also fell, dropping 0.60% to 4,441.76.
Benzinga · 09/14 18:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDHL. Analyze the recent business situations of Redhill Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDHL stock price target is 18.44 with a high estimate of 26.00 and a low estimate of 11.50.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 11.09M
% Owned: 23.74%
Shares Outstanding: 46.72M
TypeInstitutionsShares
Increased
17
422.18K
New
8
274.31K
Decreased
15
2.50M
Sold Out
17
1.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
Dror Ben-Asher
Chief Financial Officer
Micha Ben Chorin
Finance Director
Einav Nagar-Brenner
Chief Operating Officer
Gilead Raday
Senior Vice President/Director of Sales/Director of Marketing
Rob Jackson
Senior Vice President
Patricia Anderson
Senior Vice President
Reza Fathi
Senior Vice President
Robert Gilkin
Senior Vice President
David Wasserman
Chief Scientific Officer
June Almenoff
Vice President - Finance
Todd Krzyzaniak
Vice President/Director of Human Resources
Michelle Snelling
Vice President
Danielle Abramson
Vice President
Aida Bibliowicz
Vice President
Ben Martie
Vice President
Shani Maurice
Vice President
Craig Miller
Vice President
Steven Thomasian
Vice President
Reginald Williams
Other/Director
Rick Scruggs
Other
Adi Frish
Other
Guy Goldberg
Independent Director
Shmuel Cabilly
Independent Director
Alessandro Della Cha
Independent Director
Alla Felder
Independent Director
Kenneth Reed
Independent Director
Eric Swenden
Independent Director
Ofer Tsimchi
No Data
  • All
  • Financials
  • Insiders
More
About RDHL
Redhill Biopharma Ltd is an Israel-basedis a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The Company promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.